Coronary artery disease (CAD) and atrial fibrillation (AF) have emerged as new cardiovascular epidemics in the modern era posing a high risk for acute coronary and cerebrovascular events, respectively [1,2]. While antiplatelet therapy (APT) is essential for the prevention of stent thrombosis after a percutaneous coronary intervention (PCI), oral anticoagulant (OAC) is superior to APT in averting thromboembolic strokes in AF [1,2]. Approximately 20% of CAD patients have concurrent AF requiring both APT and OAC [3].
